Biotech stocks have been a disaster so far in 2016, with Nasdaq Biotech etf IBB down 20% ytd, and down 34% from its all time highs (in August 2015), and S&P Biotech etf XBI down …
Continue readingIBB
In 2015 the energy sector, measured by the S&P Energy Select etf (XLE) was the worst performing group, down 22%. In 2016, the XLE is the best performing group, up nearly 20%. As we barrel into year end, …
Continue readingLat Friday on CNBC’s Options Action, we discussed the under-performance of Biotech stocks in the first half of 2016. Meg Tirrell highlighted the large cash balances of mega-cap biotechs, and the potential for a second half …
Continue readingFor week’s now my co-panelist on CNBC’s Options Action, Carter Worth of Cornerstone Macro Research has been making the bullish case for the Biotech stocks, specifically looking at the IBB, the iShares Nasdaq Biotech etf. …
Continue readingRegardless of whether you think the bull market that started in Q1 of 2009 is over or not, one thing is fairly certain, that the breadth of the rally in large cap U.S. stocks petered …
Continue readingA little over a week ago we took a look at Bio/Pharmatech stocks and offered a way to fade the recent bounce in the sector in the very near term. It’s our belief that the scrutiny …
Continue readingOn Wednesday we laid out a bearish trade idea in the IBB, the iShares Nasdaq Biotech etf (read here) largely as a result of a poor technical set up, poor relative performance to other market …
Continue readingI guess people think it’s safe to go back in the pool. The S&P 500 (SPX) is now up 2% on the year, and just 1% from the previous all time highs. Regular readers know that …
Continue readingHere is some generally directional, untied options activity that caught my eye during Thursday’s trading: 1. XLV – biotech and pharma stocks closed near the lows of the yesterday, with the XLV closing down 1.4%, marking …
Continue readingThe volatility in the Biotech sector over the last week (like the iShares Nasdaq Biotech Index (IBB) down 7% and at one point down 10% yesterday!) has raised some eyebrows as it marks one of …
Continue reading